BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 19, 2024
See today's BioWorld Asia
See today's BioWorld
Home
» Shanghai startup Eccogene bets on small molecules for NASH
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Newco News
Shanghai startup Eccogene bets on small molecules for NASH
June 9, 2020
By
Elise Mak
No Comments
BEIJING – After his role as associate director and head of chemistry at Eli Lilly and Co., Brandeis-trained Jingye Zhou founded Eccogene Inc. in Shanghai in 2018 to focus on developing small-molecule drugs for metabolism and immune-related diseases.
BioWorld
BioWorld Asia
Newco news